<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d143" origId="Chlorthalidone"><sentence id="DrugDDI.d143.s0" origId="s0" text="Chlorthalidone may add to or potentiate the action of other antihypertensive drugs."><entity id="DrugDDI.d143.s0.e0" origId="s0.p0" charOffset="0-14" type="drug" text="Chlorthalidone"/><entity id="DrugDDI.d143.s0.e1" origId="s0.p7" charOffset="60-82" type="drug" text="antihypertensive drugs"/><pair id="DrugDDI.d143.s0.p0" e1="DrugDDI.d143.s0.e0" e2="DrugDDI.d143.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d143.s1" origId="s1" text="Potentiation occurs with ganglionic peripheral adrenergic blocking drugs."><entity id="DrugDDI.d143.s1.e0" origId="s1.p10" charOffset="36-72" type="drug" text="peripheral adrenergic blocking drugs"/></sentence><sentence id="DrugDDI.d143.s2" origId="s2" text="Medication such as digitalis may also influence serum electrolytes."><entity id="DrugDDI.d143.s2.e0" origId="s2.p11" charOffset="0-11" type="drug" text="Medication"/><entity id="DrugDDI.d143.s2.e1" origId="s2.p12" charOffset="19-28" type="drug" text="digitalis"/><pair id="DrugDDI.d143.s2.p0" e1="DrugDDI.d143.s2.e0" e2="DrugDDI.d143.s2.e1" interaction="false"/></sentence><sentence id="DrugDDI.d143.s3" origId="s3" text="Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting."/><sentence id="DrugDDI.d143.s4" origId="s4" text="Insulin requirements in diabetic patients may be increased, decreased, or unchanged."><entity id="DrugDDI.d143.s4.e0" origId="s4.p40" charOffset="0-7" type="drug" text="Insulin"/></sentence><sentence id="DrugDDI.d143.s5" origId="s5" text="Higher dosage of oral hypoglycemic agents may be required."><entity id="DrugDDI.d143.s5.e0" origId="s5.p51" charOffset="22-41" type="drug" text="hypoglycemic agents"/></sentence><sentence id="DrugDDI.d143.s6" origId="s6" text="Latent diabetes mellitus may become manifest during chlorthalidone administration."><entity id="DrugDDI.d143.s6.e0" origId="s6.p59" charOffset="52-67" type="drug" text="chlorthalidone"/></sentence><sentence id="DrugDDI.d143.s7" origId="s7" text="Chlorthalidone and related drugs may increase the responsiveness to tubocurarine."><entity id="DrugDDI.d143.s7.e0" origId="s7.p60" charOffset="0-14" type="drug" text="Chlorthalidone"/><entity id="DrugDDI.d143.s7.e1" origId="s7.p62" charOffset="27-32" type="drug" text="drugs"/><entity id="DrugDDI.d143.s7.e2" origId="s7.p66" charOffset="68-80" type="drug" text="tubocurarine"/><pair id="DrugDDI.d143.s7.p0" e1="DrugDDI.d143.s7.e0" e2="DrugDDI.d143.s7.e1" interaction="false"/><pair id="DrugDDI.d143.s7.p1" e1="DrugDDI.d143.s7.e0" e2="DrugDDI.d143.s7.e2" interaction="true"/><pair id="DrugDDI.d143.s7.p2" e1="DrugDDI.d143.s7.e1" e2="DrugDDI.d143.s7.e2" interaction="true"/></sentence><sentence id="DrugDDI.d143.s8" origId="s8" text="Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine."><entity id="DrugDDI.d143.s8.e0" origId="s8.p67" charOffset="0-14" type="drug" text="Chlorthalidone"/><entity id="DrugDDI.d143.s8.e1" origId="s8.p69" charOffset="27-32" type="drug" text="drugs"/><entity id="DrugDDI.d143.s8.e2" origId="s8.p73" charOffset="73-87" type="drug" text="norepinephrine"/><pair id="DrugDDI.d143.s8.p0" e1="DrugDDI.d143.s8.e0" e2="DrugDDI.d143.s8.e1" interaction="false"/><pair id="DrugDDI.d143.s8.p1" e1="DrugDDI.d143.s8.e0" e2="DrugDDI.d143.s8.e2" interaction="true"/><pair id="DrugDDI.d143.s8.p2" e1="DrugDDI.d143.s8.e1" e2="DrugDDI.d143.s8.e2" interaction="true"/></sentence><sentence id="DrugDDI.d143.s9" origId="s9" text="This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use."><entity id="DrugDDI.d143.s9.e0" origId="s9.p79" charOffset="67-80" type="drug" text="pressor agent"/></sentence></document>